Digital surgery company ImmersiveTouch has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ImmersiveAR augmented reality (AR) technology platform for clinical use in the operating room.
The company is now commencing ImmersiveAR’s commercialization in the U.S.
ImmersiveAR is an extension of the company’s artificial intelligence (AI)-powered suite of virtual surgical planning offerings, which aim to improve CMF (craniomaxillofacial) surgeries by lowering the traditional pre-op planning time from a week to minutes. Using it, surgical changes to bones can be simulated to plan the final aesthetic result.
This tailors the procedure to the patient’s anatomy, minimizing errors and complications.
Using ImmersiveAR, surgeons can visualize and interact with 3D virtual surgical plans that are overlaid in an OR environment. They can double-check planned movements and lower the need for intra-op trial and error.
Dr. David Hirsch, MD, DDS, senior VP of Dental Medicine at Northwell Health, said, “This virtual reality and augmented reality imaging provides remarkably detailed images of a patient’s anatomy, helping us foresee complications and reduce both planning and surgical time, resulting in a safer patient experience with fewer complications.”
“ImmersiveAR brings a new frontier in intraoperative 3D visualization,” added Jay Banerjee, CEO of ImmersiveTouch. “The surgical field has long relied on traditional two-dimensional imaging technology to navigate complex patient anatomy. Our platform introduces advanced holographic visualization to transform how surgeons plan and perform procedures.”